» Articles » PMID: 27435343

Construction and Immunological Evaluation of CpG-Au@HBc Virus-Like Nanoparticles As a Potential Vaccine

Overview
Publisher Springer
Specialty Biotechnology
Date 2016 Jul 21
PMID 27435343
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Different types of vaccines have been developed to elicit active immunization to treat various diseases, while suffer from limitation of efficacy. Herein, a novel immunostimulatory nanocomposite (CpG-Au@HBc VLP) was rationally designed by self-assembling engineered virus-like particles encapsulating CpG-gold nanoparticle conjugates through electrostatic interactions. The monodispersed and uniformly sized CpG-Au@HBc VLP showed increased CD4(+), CD8(+) T cell numbers and stronger secretion of cytokine interferon-gamma than HBc VLPs adjuvanted with conventional Freund's adjuvant. Furthermore, the use of Au nanoparticles also generated enhanced immunogenicity of CpG and VLPs on both humoral and cellular immune pathways, as followed from increased expressions of total HBc-specific antibody titer, CD4(+) T cells, CD8(+) T cells, cytokine interleukin-4, and interferon-gamma. These findings demonstrated that CpG-Au@HBc VLP nanocomposite could induce robust cellular and humoral immune response, which could be a potential vaccine for future prophylactic and therapeutic application.

Citing Articles

Pulmonary Delivery of Nonviral Nucleic Acid-Based Vaccines With Spotlight on Gold Nanoparticles.

Araujo Cirne C, Foldvari M Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025; 17(1):e70000.

PMID: 39800783 PMC: 11725562. DOI: 10.1002/wnan.70000.


Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.

Javadi M, Taghdisi Hosseinzadeh M, Soleimani N, Rommasi F Microb Pathog. 2022; 170:105687.

PMID: 35917987 PMC: 9339102. DOI: 10.1016/j.micpath.2022.105687.


Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases.

Sengupta A, Azharuddin M, Al-Otaibi N, Hinkula J Vaccines (Basel). 2022; 10(4).

PMID: 35455254 PMC: 9030786. DOI: 10.3390/vaccines10040505.


CpG-Based Nanovaccines for Cancer Immunotherapy.

Chen W, Jiang M, Yu W, Xu Z, Liu X, Jia Q Int J Nanomedicine. 2021; 16:5281-5299.

PMID: 34385817 PMC: 8352601. DOI: 10.2147/IJN.S317626.


Topical review on nano-vaccinology: Biochemical promises and key challenges.

Zaheer T, Pal K, Zaheer I Process Biochem. 2020; 100:237-244.

PMID: 33013180 PMC: 7521878. DOI: 10.1016/j.procbio.2020.09.028.


References
1.
Cohen B, Richmond J . Electron microscopy of hepatitis B core antigen synthesized in E. coli. Nature. 1982; 296(5858):677-9. DOI: 10.1038/296677a0. View

2.
Krieg A . Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5(6):471-84. DOI: 10.1038/nrd2059. View

3.
Pasek M, Goto T, Gilbert W, Zink B, Schaller H, MacKay P . Hepatitis B virus genes and their expression in E. coli. Nature. 1979; 282(5739):575-9. DOI: 10.1038/282575a0. View

4.
Agrawal S, Zhao Q . Antisense therapeutics. Curr Opin Chem Biol. 1998; 2(4):519-28. DOI: 10.1016/s1367-5931(98)80129-4. View

5.
Larson H, Jarrett C, Eckersberger E, Smith D, Paterson P . Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine. 2014; 32(19):2150-9. DOI: 10.1016/j.vaccine.2014.01.081. View